Feb. 18 at 2:06 PM
$BLGO 🚀
Clinical data finally catching up with 13 years and
$25M invested.
• ViaCLYR™ just showcased at the Boswick Symposium in Maui by top wound-care KOL Dr. Gitterle (36 cases, 4 clinics).
• Chronic, fibrotic wounds flipping to actively healing, rapid tunnel closure, big drainage reduction – across DFUs, VLUs, pressure injuries, surgical wounds.
• Strong antimicrobial performance, tissue-safe copper–iodine tech, and zero adverse events reported.
• FDA 510(k) cleared, long-acting, 7-log kill, now backed by real-world clinical experience + early stocking orders already in place.
This is exactly the kind of KOL-led, real-world validation that drives adoption and makes a wound product go worldwide. 🌎
13 years.
$25M. Early launch + Boswick data = rerate setup for
$BLGO, in my opinion. 💥
https://www.otcmarkets.com/stock/BLGO/news/BioLargo-Subsidiary-Clyra-Medical-Highlights-Key-Opinion-Leader-Presentation-of-Exceptional-ViaCLYRTM-Clinical-Results-a?id=510895